Last week's rumour that GSK was poised to make a bid to acquire IDRx and its experimental targeted therapy for a rare form of rare gastrointestinal cancer was on the money. This morning ...

setting out its plan to keep the country at the forefront of the sector. The latest announcement comes as GSK has been battling activist investor Elliott Management, which has accused the ...

We recently published a list of the 11 Best Undervalued UK Stocks to Buy Right Now. In this article, we are going to take a ...

GSK plans to launch the drug in the US in the second half of the year, and did not disclose details on pricing. The FDA approved GSK’s drug for a common type of urinary tract infection in women ...

GlobalData is the parent company of Pharmaceutical Technology. "GSK and UK researchers plan to study Shingrix and dementia risk reduction link" was originally created and published by ...

British pharmaceutical giant GSK has not met required ethical and regulatory standards in the marketing and prescription ...

The ACIP has voted to recommend the use of respiratory syncytial virus (RSV) vaccines for adults aged 50 to 59.

GSK said it plans to launch the new product in the second half of this year. Uncomplicated UTIs are infections of the bladder or urethra that develop in people who are otherwise healthy and don ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in 2022. | GSK has secured the first regulatory approval for Blenrep since the ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target ...